Effect of the <scp>glucagon‐like</scp> peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes
To investigate the hypothesis that weight loss with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide alone would lead to a greater reduction in the proportion of fat to lean tissue mass when compared to caloric restriction (CR) alone, as well as when compared to treatment with sita...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Saesneg |
| Cyhoeddwyd: |
2023
|
| Mynediad Ar-lein: | https://doi.org/10.1111/dom.15113 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|